

UnitedHealthcare Pharmacy  
Clinical Pharmacy Programs

Program Number	2026 P 1507-1
Program	Prior Authorization/Notification
Medication	Kygevvi® (doxecitine and doxribtimine)
P&T Approval Date	1/2026
Effective Date	4/1/2026

**1. Background:**

Kygevvi (doxecitine and doxribtimine) is a combination of doxecitine and doxribtimine, both pyrimidine nucleosides, indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years.

**2. Coverage Criteria<sup>a</sup>:**

<p><b>A. <u>Initial Authorization</u></b></p> <p>1. <b>Kygevvi</b> will be approved based upon <b>both</b> of the following criteria:</p> <p style="margin-left: 40px;">a. Diagnosis of thymidine kinase 2 deficiency (TK2d)</p> <p style="text-align: center;"><b>-AND-</b></p> <p style="margin-left: 40px;">b. Age of symptom onset ≤ 12 years</p> <p style="text-align: center;"><b>Authorization will be issued for 12 months.</b></p> <p><b>B. <u>Reauthorization</u></b></p> <p>1. <b>Kygevvi</b> will be approved based on the following criterion:</p> <p style="margin-left: 40px;">a. Documentation of positive clinical response to Kygevvi therapy</p> <p style="text-align: center;"><b>Authorization will be issued for 12 months.</b></p> <p><sup>a</sup>State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.</p>
---

**3. Additional Clinical Rules:**

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place.

#### 4. Reference:

1. Kygeevi [package insert]. Smyrna, GA: UCB, Inc.; November 2025.

Program	Prior Authorization/Notification - Kygeevi (doxycitine and doxribtimine)
<b>Change Control</b>	
1/2026	New program